Fig. 3From: A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapiesAnnual total direct cost per patient as a percentage of GDP per capita. For studies with an annual cost over a range of years, the last year is shown in the graph. A line of best fit is shown for countries that had ≥ 2 studies (US and Canada)Back to article page